Beningn prostatic hyperplasia in dogs
Reading File
Finding Sources
Finding Sources
Searching PubMed
benign prostatic hyperplasia dog canine
Finding Sources
Finding Sources
Searching PubMed
canine prostatic hyperplasia diagnosis treatment
Reading Article
Reading Article
Reading File
Searching the Web
benign prostatic hyperplasia dogs clinical signs diagnosis treatment castration finasteride osaterone
I now have solid material from multiple sources. Let me compile a comprehensive answer.
Benign Prostatic Hyperplasia (BPH) in Dogs
BPH is the most common prostatic disorder in sexually intact male dogs. It is an androgen-dependent, age-related condition, distinct from the obstructive syndrome seen in men because of key anatomical differences.
Etiology and Pathophysiology
BPH develops due to continuous androgenic stimulation of the prostate, primarily by dihydrotestosterone (DHT), which is converted from testosterone by 5-alpha-reductase within prostatic cells. As dogs age, an altered androgen:estrogen ratio promotes stromal and glandular hyperplasia. Virtually all intact male dogs develop some degree of BPH by age 6, with histological changes beginning as early as 2.5 years.
An important anatomical point noted in Campbell-Walsh Urology: the dog is the only other species besides humans known to develop naturally occurring BPH, but clinical signs of urinary obstruction are rare in dogs because the canine prostate lacks a capsule. In humans, the capsule transmits the pressure of tissue expansion to the urethra, raising urethral resistance. Without a capsule, canine BPH causes different predominant signs (rectal/perineal pressure rather than obstructive uropathy).
- Scottish Terriers appear to be disproportionately and more severely affected than other breeds.
- 99% of affected dogs are non-castrated, which underscores testosterone's central role.
Clinical Signs
Many dogs are subclinically affected, discovered incidentally on rectal exam. When signs are present, they include:
| Category | Signs |
|---|---|
| Hemorrhagic | Persistent/intermittent hematuria, hemospermia, hemorrhagic or serosanguinous preputial/urethral discharge |
| Digestive | Tenesmus, constipation, ribbon-shaped feces (due to prostatic enlargement compressing the rectum), anorexia, weight loss |
| Urinary | Dysuria, urinary incontinence (less common than in men) |
| Reproductive | Infertility, reduced sperm quality, elevated nitric oxide in spermatozoa (associated with sperm oxidative stress) |
Signs may worsen when the dog is exposed to estrous females (increased LH and testosterone output).
Diagnosis
Diagnosis rests on a combination of:
- History and physical examination - nonpainful, symmetrically enlarged prostate on rectal or transabdominal palpation.
- Transabdominal ultrasonography - the best method; assesses size, echotexture, and presence of cysts (parenchymal or periprostatic). Prostatic cysts are common complications.
- Canine Prostate-Specific Esterase (CPSE) - a biomarker that is elevated in BPH; useful for monitoring treatment response (baseline typically >200-300 ng/mL in BPH).
- Fine needle aspiration (FNA) / cytology - used to differentiate BPH from prostatitis, abscess, or neoplasia.
- Contrast-Enhanced Ultrasound (CEUS) - an emerging tool that can quantify prostatic perfusion (wash-in and wash-out phases of contrast agent), useful for monitoring treatment effect, particularly with osaterone acetate.
- Haematology/biochemistry - typically normal in uncomplicated BPH; abnormalities suggest prostatitis, abscess, or neoplasia.
Differential Diagnoses
- Bacterial prostatitis (painful prostate, systemic signs, leukocytosis)
- Prostatic abscess
- Prostatic cysts
- Prostatic carcinoma (rare but more common in neutered dogs)
- Paraprostatic cysts
Treatment
Surgical
Castration (orchiectomy) is the treatment of choice for dogs not used for breeding. It eliminates the androgenic drive and causes prostatic involution within 3-4 weeks, with volume reduction up to 70% over 3 months. It is curative.
Medical (for breeding/show dogs, or as a bridge to surgery)
| Drug | Class | Dose | Mechanism | Notes |
|---|---|---|---|---|
| Osaterone acetate (Ypozane, Virbac) | Steroidal anti-androgen | 0.5 mg/kg PO q24h x 7 days | Competes with DHT at prostatic androgen receptors; blocks testosterone transport into prostate | Reduces volume ~27% by week 1, ~40% by week 2; repeat every ~6 months; 80% of dogs show improvement by day 7 |
| Deslorelin acetate (Suprelorin) | GnRH agonist implant | 4.7 mg SC implant | Initial LH surge then downregulation of HPG axis; sustained testosterone suppression | Slower onset (~21 days); longer duration (up to 12 months); no relapses reported at 36 weeks vs. osaterone; causes temporary infertility |
| Finasteride | 5-alpha-reductase inhibitor | ~0.1-0.5 mg/kg PO q24h (or ~2.5 mg total dose in small breeds) | Blocks DHT synthesis | Reduces prostatic volume; preserves fertility better than osaterone; slower response; used in breeding dogs |
| Delmadinone acetate | Progestogen | Variable | Anti-androgenic; suppresses LH | Less used; risk of diabetes mellitus with long-term use |
Osaterone vs. deslorelin comparison (2025 RCT data): Both are effective and safe. Osaterone achieves faster remission (80% by day 7); deslorelin has longer duration with no relapses at 36 weeks. Osaterone does not cause the testosterone "flare" seen initially with GnRH agonists.
Complications
Untreated BPH predisposes to:
- Bacterial prostatitis (the blood-filled prostatic tissue is a nidus for infection)
- Prostatic cysts and paraprostatic cysts
- Prostatic abscess (life-threatening)
- Reduced fertility and sperm quality - elevated reactive oxygen species (nitric oxide) have been documented in spermatozoa of BPH-affected dogs
Key Points Summary
- BPH affects virtually all intact male dogs >6 years, beginning histologically as early as age 2-3.
- Most dogs are subclinically affected or show hemorrhagic discharge rather than urinary obstruction (unlike humans).
- The lack of a prostatic capsule in dogs explains the different clinical presentation compared to men.
- Castration is curative and the first-line treatment in non-breeding dogs.
- Osaterone acetate (7-day oral course, repeat q6 months) is the leading medical option; deslorelin implants provide longer-lasting suppression.
- CPSE is a useful diagnostic and monitoring biomarker.
- BPH is a significant predisposing factor for prostatitis and abscess.
Sources: Campbell-Walsh Urology (comparative anatomy section); Merck Veterinary Manual - BPH in Dogs; Derakhshandeh et al., Vet Med Int 2025 [PMID: 40687184]; Pettina et al., Animals 2024 [PMID: 38891730] (CEUS and osaterone monitoring).
This is a shared conversation. Sign in to Orris to start your own chat.